US1055321053 - ADR

Overall **BAK** gets a fundamental rating of **2** out of 10. We evaluated **BAK** against 83 industry peers in the **Chemicals** industry. Both the profitability and financial health of **BAK** have multiple concerns. **BAK** is valued correctly, but it does not seem to be growing.

Looking at the **Return On Assets**, with a value of **-5.12%**, **BAK** is doing worse than **79.52%** of the companies in the same industry.

With a **Return On Equity** value of **-93.87%**, **BAK** is not doing good in the industry: **89.16%** of the companies in the same industry are doing better.

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -5.12% | ||

ROE | -93.87% | ||

ROIC | N/A |

ROA(3y)2.32%

ROA(5y)1.54%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

The **Profit Margin** and **Operating Margin** are not available for **BAK** so they could not be analyzed.

Industry Rank | Sector Rank | ||
---|---|---|---|

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 2.66% |

OM growth 3Y-5.67%

OM growth 5Y-20.61%

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-2.5%

GM growth 5Y-14.73%

There is no outstanding debt for **BAK**. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

With a **Altman-Z score** value of **0.96**, **BAK** is not doing good in the industry: **73.49%** of the companies in the same industry are doing better.

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 10.77 | ||

Debt/FCF | N/A | ||

Altman-Z | 0.96 |

ROIC/WACCN/A

WACC8.05%

A Current Ratio of **1.54** indicates that **BAK** should not have too much problems paying its short term obligations.

Industry Rank | Sector Rank | ||
---|---|---|---|

Current Ratio | 1.54 | ||

Quick Ratio | 1.03 |

EPS 1Y (TTM)-61.19%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-414.61%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-7.85%

The **Earnings Per Share** is expected to grow by **39.03%** on average over the next years. This is a very strong growth

The **Revenue** is expected to grow by **6.47%** on average over the next years.

EPS Next Y33.59%

EPS Next 2Y51.94%

EPS Next 3Y39.03%

EPS Next 5YN/A

Revenue Next Year8.44%

Revenue Next 2Y8.36%

Revenue Next 3Y6.47%

Revenue Next 5YN/A

The **Price/Earnings Ratio** is negative for **BAK**. In the last year negative earnings were reported.

Based on the **Price/Forward Earnings** ratio of **9.84**, the valuation of **BAK** can be described as reasonable.

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 9.84 |

Based on the **Enterprise Value to EBITDA** ratio, **BAK** is valued a bit more expensive than the industry average as 60.24% of the companies are valued more cheaply.

Industry Rank | Sector Rank | ||
---|---|---|---|

P/FCF | N/A | ||

EV/EBITDA | 15.42 |

The low **PEG Ratio(NY)**, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as **BAK**'s earnings are expected to grow with **39.03%** in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y51.94%

EPS Next 3Y39.03%

No dividends for **BAK**!.

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

**BRASKEM SA-CLASS A- ADR**

NYSE:BAK (8/14/2024, 7:04:00 PM)

After market: 5.9 -0.11 (-1.83%)**6.01**

**0 (0%) **

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap2.39B

Analysts

Price Target

Dividend

Industry Rank | Sector Rank | ||
---|---|---|---|

Dividend Yield | N/A |

Dividend Growth(5Y)

DP

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

Industry Rank | Sector Rank | ||
---|---|---|---|

PE | N/A | ||

Fwd PE | 9.84 | ||

P/S | |||

P/FCF | |||

P/OCF | |||

P/B | |||

P/tB | |||

EV/EBITDA |

EPS(TTM)

EY

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

Industry Rank | Sector Rank | ||
---|---|---|---|

ROA | -5.12% | ||

ROE | -93.87% | ||

ROCE | |||

ROIC | |||

ROICexc | |||

ROICexgc | |||

OM | N/A | ||

PM (TTM) | N/A | ||

GM | 2.66% | ||

FCFM |

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.79

Health

Industry Rank | Sector Rank | ||
---|---|---|---|

Debt/Equity | 10.77 | ||

Debt/FCF | |||

Debt/EBITDA | |||

Cap/Depr | |||

Cap/Sales | |||

Interest Coverage | |||

Cash Conversion | |||

Profit Quality | |||

Current Ratio | 1.54 | ||

Quick Ratio | 1.03 | ||

Altman-Z |

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)-61.19%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y33.59%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y